Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: Cancer Chemother Pharmacol

Search In Journal Title:

Abbravation: Cancer Chemotherapy and Pharmacology

Search In Journal Abbravation:

Publisher

Springer-Verlag

Search In Publisher:

ISSN

1432-0843

Search In ISSN:
Search In Title Of Papers:

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial

Authors: Carmela Pisano, Alessandro Morabito, Roberto Sorio, Enrico Breda, Rossella Lauria, Vittorio Gebbia, Laura Scaltriti, Simona Scalone, Vittorina Zagonel, Stefano Greggi, Gerardo Beneduce, Simona Losito, Ciro Gallo, Massimo Di Maio, Valeria Forestieri, Sandro Pignata,

Publish Date: 2009/03/06
Volume: 64, Issue:5, Pages: 1021-1027
PDF Link

Abstract

Capecitabine is an oral chemotherapeutic agent, already used in breast and colon cancer. Previous data showed encouraging results in the treatment of recurrent ovarian cancer. The aim of this study was to describe activity and toxicity of capecitabine in patients with platinum resistant or refractory ovarian cancer.Patients were eligible if they had cytologically or histologically proven epithelial ovarian cancer, refractory or resistant to prior platinum-containing chemotherapy. Capecitabine was administered at the dose of 1,250 mg/m2 twice daily on days 1–14 of a 21-day cycle for a maximum of six cycles. The primary end point of the study was activity in terms of objective response rate in according to RECIST criteria. A two-stage minimax design for phase II studies was used: at least four objective responses had to be reached among 32 evaluable patients to define the treatment active.Between March 2006 and October 2007, 36 patients were enrolled. All patients had ovarian cancer and 83.3% had previously received two or three lines of chemotherapy. Thirty-two patients were evaluable for response and included in the activity analysis. The objective response rate was 3.1% [95% exact confidence interval (CI): 0.08–16.22%], lower than the threshold required to define the treatment as active. The median progression free survival was 68 days (95% CI: 65–120). Haematological toxicity was not frequent. Nausea and fatigue were common, but never severe, and they were observed in 13 (37.1%) and 12 (34.2%) patients, respectively. Diarrhoea occurred in 11 patients (31.5%) and it was of grade 3 in 8.6% of cases. Grade 1–2 stomatitis was observed in seven patients (20%). Cardiovascular toxicity was reported in two cases, including a death for pulmonary embolism.Partially supported by AIRC. The Authors thank Alfonso Savio for informatic assistance. Roche supported the study giving capecitabine at no cost and a research grant, without any right of property of data nor any influence on protocol planning, study conduction, analysis and interpretation.


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
  2. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
  3. Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab
  4. Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
  5. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
  6. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
  7. CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil
  8. A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
  9. Preclinical pharmacokinetics of MFGR1877A
  10. Voreloxin
  11. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model
  12. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib
  13. Population pharmacokinetics of HM781-36 (poziotinib)
  14. Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis
  15. Efficacy and safety of motesanib
  16. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
  17. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
  18. HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells
  19. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent
  20. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma
  21. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite
  22. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
  23. Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients
  24. SNS-314

Search Result:



Help video to use 'Paper Search Console'